Sclc cell lines

SCLC cell lines were purchased from American Type Culture Collection and maintained as recommended. All cell lines tested negative for mycoplasma (Lonza; MycoAlert) and were short tandem repeat verified at the Johns Hopkins Fragment Analysis Facility within 6 months of use. ABT-737 was obtained from Abbott Laboratories (now Abbvie) and purchased from Active Biochem (A-1002). For in vivo use, ABT-737 and etoposide (Accord Healthcare, Inc.) were prepared as previously described (18 (link)). Rapamycin (LC Laboratories) was stored in 100% ethanol at 50 mg/mL. For in vivo use, Rapamycin vehicle was 82% PBS/5% Tween-80/5% polyethylene glycol 400/8% ethanol. AZD8055 (S1555), BEZ235 (S1009), everolimus (S1120), LY294002 (S1105), and wortmannin (S2758) were purchased from Selleck Chemicals. Dimethyl sulfoxide (DMSO) was used as a vehicle for all in vitro experiments.

SCLC cell lines were purchased from American Type Culture Collection. Cell lines were maintained as recommended. All cell lines were verified by Short Tandem Repeat fingerprinting (DDC Medical) and tested negative for mycoplasma within 6 months of use. Talazoparib (BMN-673) and veliparib (ABT-888) were aliquoted and stored at −20°C after preparation in dimethyl sulfoxide (DMSO). All in vitro experiments were performed in 1% (v/v) DMSO. For in vivo dosing, talazoparib was administered with 10% dimethylacetamide (Sigma #270555) and 5% Kolliphor HS 15 (Sigma #42966) in PBS. Details about preparation are as previously described(18 (link)).

SCLC cell lines were purchased from American Type Culture Collection and maintained as recommended. All cell lines tested negative for mycoplasma and were short tandem repeat verified/authenticated within 6 months of use. Dimethyl sulfoxide (DMSO) was used as a vehicle for all in vitro experiments. Talazoparib was obtained from Biomarin or Selleck Chemicals. For in vivo use, Talazoparib was prepared in dimethylacetamide (DMAc; 270555, Sigma) in 1 mg/mL concentration then diluted 1:10 in 5 parts Kolliphor HS/85 parts PBS and stored at 4°C and discarded after 14 days. For in vivo dosing, Talazoparib was diluted in sterile PBS to 0.2mg/mL for weight-based dosing by oral gavage. Talazoparib vehicle was 2% DMAc/1% Kolliphor HS/ 97% PBS. Temozolomide (S1237; Selleck Chemicals) for in vivo use was prepared in 0.5% carboxymethylcelluse sodium salt in water for weight-based dosing by oral gavage.

SCLC cell lines were obtained from the American Type Culture Collection (ATCC). Cells were maintained in accordance to the ATCC guidelines. NCI-H69 and NCI-H1417 were cultured in RPMI-1640 supplemented with 100U/ml penicillin, 100μg/ml streptomycin and 10% fetal bovine serum (FBS). NCI-H510A were cultured in DMEM-F12 supplemented with sodium pyruvate (1mM), insulin-transferrin-selenium (10μg/ml, 5.5μg/ml, 0.0067μg/ml), 30nM hydrocortisone, 10nM beta-estradiol, 100U/ml penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum (FBS). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂ and 95% air. All lines were STR profiled for authentication. Ex vivo PDX models were cultured in DMEM-F12 supplemented with sodium pyruvate (1mM), insulin-transferrin-selenium (10μg/ml, 5.5μg/ml, 0.0067μg/ml), 30nM hydrocortisone, 10nM beta-estradiol, 100U/ml penicillin, 100μg/ml streptomycin and 10% fetal bovine serum (FBS). All experiments were performed on low passage ex vivo PDX cultures. 293TN producer cell line was cultured in DMEM supplemented with 100U/ml penicillin, 100μg/ml streptomycin and 10% fetal bovine serum (FBS).